Q-omics provides the consensus-scored CCL13 profile across patient tissues and cancer cell-line models. CCL13 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CCL13 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, CCL13 RNA expression shows 15,374 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, COAD, and LSCC as cancer lineages where CCL13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCL13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCL13 survival associations across molecular data types. CCL13 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCL13 RNA expression–survival associations across cancer types. High CCL13 expression shows unfavorable associations in KIRC, KIRP and MESO, but favorable associations in SKCM, UCEC and BLCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for CCL13 RNA expression.
This table summarizes CCL13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for CCL13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCL13 shows lower tumor expression in COAD, LUSC, KICH and BRCA and higher tumor expression in THCA and HNSC. The COAD box plot shows higher CCL13 RNA expression in normal versus tumor tissue (log2 FC = −2.019, t-test p < 0.001).
This table shows molecular features associated with CCL13 in patient tissues and cancer cell lines. In patient samples, CCL13 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCL13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and UPPER_AERODIGESTIVE_TRACT.
